|Year : 2017 | Volume
| Issue : 1 | Page : 11-17
Efficacy and safety of teneligliptin
Awadhesh Kumar Singh
Department of Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal, India
|Date of Web Publication||19-Dec-2016|
Awadhesh Kumar Singh
Department of Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Singh AK. Efficacy and safety of teneligliptin. Indian J Endocr Metab 2017;21:11-7
Incretin-based therapies (IBT) including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been the cornerstone of therapy for type 2 diabetes mellitus (T2DM) since the evolution of incretin science. DPP-4Is are particularly popular in the treatment of T2DM as they are oral drugs, less costlier than GLP-RAs, with modest to moderate glucose lowering similar to sulfonylureas (SU) depending on the baseline glycemic load. DPP-4Is carries novel mechanism of action and also have additional potential to protect from hypoglycemia, through unique glucagon dynamics. Indeed, consensus statements from the American College of Endocrinology/American Association of Clinical Endocrinologist and the Latin American Diabetes Association consider DPP-4I ahead of SU, mainly driven by their lower risk of hypoglycemia as well as weight neutrality.,
Moreover, Asians (mainly East Asians) have also been found to respond comparatively better to IBT, compared to Caucasian. However, incretin response in South Asians (including Indians) appears to be different from East Asians and thus currently there is no clear consensus whether Indians also exhibit exaggerated response to IBT, like East Asians. Consequently, at least 11 different compounds of DPP-4Is have been made available worldwide, of which mostly available in Japan. In India, 4 DPP-4Is are already available and marketed that includes sitagliptin, vildagliptin, saxagliptin, and linagliptin. Recently, two newer molecule teneligliptin and gemigliptin have been added to this segment. Importantly, teneligliptin has been already approved and marketed product in Japan since 2012 and in Korea since 2014. However, teneligliptin is neither approved in the USA or in Europe although it was registered in the US Food and Drug Administration (FDA) for Phase 1 clinical development in 2007 and Phase 2 clinical developments in European Medicines Agency in 2009, without any further progress.
Recently an Indian study by Suryawanshi et al, reported the results of a 16-week, multicentric, double-blind, placebo-controlled, Phase 3 studies of teneligliptin 20 mg daily in drug naive T2DM patients. This study (N = 237) reported a significant −0.55% glycated hemoglobin (HbA1c) reduction (placebo-subtracted) in teneligliptin arm (P = 0.0043) compared to control. While a significant reduction in 2 h postprandial glucose (PPG) (−25.8 mg/dl, P = 0.0070) versus placebo was observed, an insignificant reduction in fasting plasma glucose (FPG) was seen (−8.8 mg/dl, P = 0.18) in teneligliptin 20 mg arm. Similarly, higher percentage of patient achieved the target HbA1c of <7% in teneligliptin arm (43.4% vs. 27.3%, P = 0.026) compared to the control and “overall” the drug was well tolerated.
Here, we aimed to systematically review the efficacy and tolerability of teneligliptin and put a perspective from the available evidence.
| Review Method|| |
A PubMed search was made using MeSH word “teneligliptin,” “cardiovascular (CV) outcome,” and “DPP-4Is” and all the clinical trials published till date in English language were retrieved. Dossier of teneligliptin approval from Japan FDA was also retrieved, and subsequently, all the data chronologically analyzed.
Pharmacological properties of teneligliptin
Teneligliptin appears to possess a different chemical structure when compared to other DPP-4Is and consists of five consecutive cyclic rings. An X-ray co-crystallography study of teneligliptin found that the key interaction between the phenyl ring on the pyrazole and binding to “anchor lock domain” of S2 extensive subsite, boosts its potency, duration of action in vivo, and enhances selectivity. However, whether this interaction translates into any higher percentage of DPP-4I remains a matter of conjecture. Nonetheless, the mean t1/2 of teneligliptin is ~20 h for 10 and 20 mg dosage in humans. With regards to pharmacodynamics, about 34.4% of teneligliptin is excreted unchanged via the kidney and the remaining 65.6% teneligliptin is metabolized and eliminated via renal and hepatic excretion. Any degree of renal impairment does not affect the maximum plasma teneligliptin concentration after a single oral dose of 20 mg. This pharmacodynamic profile suggests that teneligliptin can be administered in patients with any degree of renal impairment without dose adjustments. However, the mean ratios for maximal plasma concentration in subjects with mild and moderate hepatic impairment were 25% and 38% higher than in healthy subjects, respectively, and those for the area under the curve (AUC0–∞) were 46% and 59% higher than in healthy subjects, respectively. This indicates that caution may be needed when administering teneligliptin to subjects with hepatic impairment.
Teneligliptin metabolized by CYP3A4 and flavin-containing monooxygenases (FMO1 and FMO3) and it is a weak inhibitor of CYP2D6, CYP3A4, and FMO in vitro, but it has neither any inhibitory effect nor inducing effect. There were no clinically relevant drug–drug interactions when teneligliptin was coadministered with ketoconazole (a potent CYP3A4 and P-glycoprotein inhibitor), metformin, or canagliflozin in healthy volunteers.,,
Although teneligliptin has higher potency, it has moderate selectivity to DPP-4 receptors. The IC50 values of teneligliptin against other DPP-enzymes including DPP-8 and DPP-9 are ~160–850 times greater than that for DPP-4, whereas IC50 for fibroblast protein activation is >10,000 times greater than that for DPP-4.,
The most important pharmacodynamic parameter for any DPP-4Is that translates to clinical efficacy is the extent of percentile DPP-4 inhibition. While percentage of DPP-4 inhibition was 81.3 and 89.7% within 2 h after teneligliptin 10 and 20 mg, respectively, percentage inhibition of plasma DPP-4 activity at 24 h after administration was 53.1 and 61.8% in the teneligliptin 10 and 20 mg group, respectively, in a 4-week study conducted by Eto et al. Another study by Nabeno et al. demonstrated that the percentage inhibition of plasma DPP-4 activity 24 h after administration of 20 and 40 mg dose of teneligliptin was varying somewhere between 53.9–66.9% and 59.8%, respectively. Besides, only 80 mg doses of teneligliptin exhibited >80% (72–85%) plasma DPP-4 inhibition at 24h after administration. [Table 1] summarizes the extent of DPP-4 inhibition at various time point with different dosage of teneligliptin. Interestingly, both 10 and 20 mg teneligliptin demonstrated higher concentrations of plasma active GLP-1, compared to placebo even at 24 h after administration. Moreover, the differences in AUC0–2h for plasma active GLP-1 concentration between both teneligliptin treated groups and placebo were statistically significant (P < 0.001).
|Table 1: The percentage of dipeptidyl peptidase-4 inhibition with various dosages of teneligliptin (adapted from Japan Pharmaceuticals and Medical Devices Agency dossier)|
Click here to view
Efficacy of teneligliptin
In a very small (n = 99), 4 weeks, Japanese, Phase 2 clinical trial, the teneligliptin 10 mg has been shown to reduce 2 h PPG after each meal (breakfast, lunch, and dinner) by −50.7, −34.8, and −37.5 mg/dl, respectively, against placebo in a drug naive T2DM patients (all, P < 0.001). Similarly, teneligliptin 20 mg also reduced 2 h PPG after each meal by −38.1, −28.6, and −36.1 mg/dl, respectively, against placebo at breakfast, lunch, and dinner (all P significant). Kutoh et al. in a 3-month study of 31 drug naive Japanese T2DM patients, evaluated teneligliptin daily 20 mg as a monotherapy. This study found a significant reduction in HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%, P < 0.00001) and fasting blood glucose (from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL, P < 0.0002) from the baseline. In addition, homeostasis model assessment-B (HOMA-B) levels significantly increased, whereas high HOMA-R levels significantly decreased. However, a significant increase (P < 0.05) in uric acid was also observed in this study.
Teneligliptin has also been studied for 12 weeks or longer placebo-controlled trials as monotherapy (in another Japanese Phase 2 and one Korean Phase 3 study), as a combination therapy to glimepiride, pioglitazone in Japanese T2DM patients (in Phase 3 trials) and as an add-on to metformin in Korean T2DM patients (in Phase 3 trial).,,,, Two out of the three Phase 3 trials also had an open-label, 40 weeks extension phase after initial 12 weeks of blinding period. In both their extension studies, all patients were given teneligliptin 20 mg daily and up-titrated to teneligliptin 40 mg daily at or after 24 weeks, if HbA1c were >7.3%., [Table 2] summarizes the results from all these studies including the Indian data.
|Table 2: Efficacy of teneligliptin 20 mg daily in type 2 diabetes in phase 2 or 3, randomized, double-blind, placebo-controlled multicenter trials|
Click here to view
The efficacy and safety when teneligliptin dose is increased to 40 mg in patients with insufficient response to 20 mg are also available from one of the integrated analyses of the Japanese long-term treatment study as a review file by Japan Pharmaceuticals and Medical Devices Agency (PMDA). This integrated analysis reported the pooled data of three studies including two published studies , and one unpublished study. In this analysis, the teneligliptin dose was to be increased to 40 mg, if HbA1c target met the criteria for dose increase as per the protocol. Interestingly, results from the pooled data found that the dose was required to be increased to 40 mg in 45.9% (290 of 632 patients) of patients. Of 275 patients (275 of 290 patients) whose HbA1c data were available at 12 weeks after the dose increase, 30.9% (85 of 275 patients) showed a ≥0.3% decrease in HbA1c when switched to teneligliptin 40 mg. Overall, HbA1c level decreased to <7.0% at 12 weeks after the dose increase, in 15.6% of patients. Regarding safety after the dose escalation, a marginal increase in incidence of adverse events (AEs) were noted in teneligliptin 40 mg (73.8% versus 63.4% in teneligliptin 20 mg).
The long-term efficacy of teneligliptin has also been studied in two 52-week, open-label, multicenter, interventional Japanese studies and data presented as a pooled analysis. The changes in HbA1c (mean ± standard deviation [SD]) from baseline to week 52 were −0.63 ± 0.65% in the teneligliptin monotherapy group, −0.76 ± 0.70% in the glinide combination therapy group, −0.78 ± 0.75% in the biguanide combination therapy group, −0.89 ± 0.64% in the alpha-glucosidase inhibitor combination therapy group, and −0.81 ± 0.76% in the SU combination therapy group. Nevertheless, reductions in HbA1c were dependent on the baseline values, with reductions of −0.26 ± 0.30% for HbA1c <7.0% at baseline, −0.57 ± 0.47% for HbA1c 7.0–8.0% at baseline, and −1.02 ± 0.87% for HbA1c >8.0% at baseline.
In a very small (n = 43), short-term (28 weeks), observational, Japanese study, Otsuki et al. evaluated the efficacy and safety of teneligliptin (n = 14) to controls (n = 29) on existing antidiabetic therapy, in adults with T2DM, who had end-stage renal disease. The study found no significant difference (P = 0.057) between the teneligliptin and control group for changes in HbA1c levels at 24 weeks although significant drop in HbA1c was noticed in 7 patients on teneligliptin who switched from other antidiabetic therapy. Currently, no randomized controlled trial in renal-compromised patients has been published with teneligliptin.
Two studies that have studied the teneligliptin effect on glucose variation also merit special mention although they are too short in duration and too small in a number of patient included and therefore may not be very conclusive. In one Japanese study in T2DM patients receiving insulin therapy (n = 26), with or without other antidiabetes drugs, teneligliptin was found to improve indices of glucose fluctuations (the SD of 24 h glucose levels and mean amplitude of glycemic excursions [MAGE]) using continuous glucose monitoring without inducing hypoglycemia. In another very small (n = 10) report from Japanese T2DM patients, 3 days of teneligliptin on ongoing insulin therapy found to improve 24 h glucose levels, SD of 24 h glucose levels, and MAGE. Collectively, these results suggest improvement in glucose fluctuations with teneligliptin.
Safety and tolerability of teneligliptin
Teneligliptin as a monotherapy or add-on therapy to other agents such as glimepiride, metformin, and pioglitazone, was generally well tolerated in patients with T2DM participating in clinical trials.
In monotherapy study, adverse drug reactions (ADRs) and AEs occurred in ≥5% of patients in any group were nasopharyngitis, positive urine ketone body, urine glucose, and urinary protein. The incidence of ADRs was not significantly different among the four groups although the adverse rate tended to be higher in the teneligliptin 40 mg group. All ADRs were categorized as mild in intensity by the investigator.
In Phase 3 add-on to glimepiride study, the incidence rates of serious AEs were similar in both groups at week 12. In Phase 3 add-on to pioglitazone, specific AEs occurred in >5% and included nasopharyngitis and peripheral edema. Hypoglycemia was reported in two patients (1.9%) in the teneligliptin group at week 12. In the pooled 52 weeks safety analysis, treatment-related hypoglycemia occurred with an overall incidence of 3.4% in teneligliptin recipients, with all episodes of mild intensity. The incidence of hypoglycemia was numerically higher in the teneligliptin plus SU (10.1%) and teneligliptin plus glinide (5.0%) groups than in the teneligliptin monotherapy (2.5%), teneligliptin plus biguanide (1.1%), or teneligliptin plus α-glucosidase inhibitor (1.3%) groups. Thyroid cancer was observed in one patient in the teneligliptin monotherapy group.
Cardiac safety of teneligliptin
Overall, in all published randomized controlled trial, no serious cardiac events have been attributable to teneligliptin.
Interestingly, a thorough QT/QTc evaluation study of teneligliptin 40 and 160 mg actively compared to moxifloxacin found a significant increase in latter dose. Teneligliptin 40 mg/day which is currently the maximal recommended dose prolonged the placebo-corrected QTcF (QTc corrected for heart rate) by 4.9 ms after 3 h. The 160 mg/day of teneligliptin significantly increased the QTcF by 11.2 ms after 1.5 h of the drug was administered, almost similar to 12.1 ms of QTcF prolongation as observed 2 h after moxifloxacin. The Japanese PMDA also concluded “In the Phase III studies of teneligliptin, patients being treated for arrhythmia, patients with a history of ventricular tachycardia, and patients with abnormality in resting standard 12-lead electrocardiography (ECG) at the start and end of the run-in period were excluded. Therefore, the risks of QTc interval prolongation and arrhythmia in these patients have not been investigated. Furthermore, since the timing for ECG measurement was not specified in the Phase III studies, the possibility cannot be excluded that the effect of teneligliptin on QTc interval prolongation was not thoroughly investigated. In addition, taking into account that there are diabetic patients who have concurrent diseases such as arrhythmia and ischemia, and that teneligliptin may be administered to such patients for a long period of time, it is deemed necessary to raise caution in administering teneligliptin to these patients and to collect information on proarrhythmic risk via postmarketing surveillance.” [Table 3] summarizes the QTc prolongation with various dosages of teneligliptin.
|Table 3: QTc prolongation with various dosage teneligliptin (adapted from Japan Pharmaceuticals and Medical Devices Agency dossier)|
Click here to view
This may also suggest that a great caution may be required in patients who are prone to QT prolongation such as those with episodes of bradycardia, ischemic heart diseases, heart failure, and hypokalemia. In addition, the coadministration of teneligliptin with drugs known to cause QT prolongation such as Class IA or Class III antiarrhythmic drugs must be performed with great caution.
Extraglycemic effect of teneligliptin
Experimental studies conducted with teneligliptin found notable improvement in metabolic features in rat and mice., Teneligliptin 20 mg also appeared to improve vascular endothelial function at 2 weeks in a study of 11 elderly T2DM patients. Hashikata et al. in a 3-month study of 29 Japanese T2DM patients evaluated the effect of teneligliptin 20/40 mg daily on left ventricular (LV) function using echocardiography at baseline and at the end of the study. A significant improvement in both LV systolic and diastolic function was observed at the end of 3 months. LV ejection fraction improved from 62.0 ± 6.5% to 64.5 ± 5.0%, P = 0.01 and peak early diastolic velocity/basal septal diastolic velocity (E/e′) ratio improved from 13.3 ± 4.1 to 11.9 ± 3.3, P = 0.01. In addition, a significant improvement in endothelial function was also observed, as measured by reactive hyperemia peripheral arterial tonometry (RHPAT) index (RHPAT index improved from 1.58 ± 0.47 to 2.01 ± 0.72, P < 0.01).
Collectively, available data may suggest that teneligliptin is an important addition to the class of DPP-4I in the treatment of T2DM and is better than placebo.
| Summary|| |
DPP-4Is are well established and a convenient once/twice daily oral regimen in the treatment of T2M, with a very low intrinsic potential of hypoglycemia and also bodyweight neutral. However, as a class, when there are already four molecules available in India with ample of scientific evidence available, a critical look is highly desirable.
With regard to pharmacological properties, teneligliptin is moderately selective to DPP-4 against DPP-8 and DPP-9 receptors, in vitro studies. Available evidence although indirect one (no head-to-head study available) suggests that teneligliptin selectivity to DPP-4 is lower than sitagliptin and linagliptin and perhaps better than saxagliptin and vildagliptin. Although the preclinical studies suggested several adverse effects including skin reaction, lymphopenia, and increased in mortality related to DPP-8 and or DPP-9 inhibition, importance of such finding has been questioned in human studies., Nevertheless, lymphopenia with saxagliptin (prescribing information) and higher potential of skin reaction observed with vildagliptin may theoretically suggest in favor of selective DPP-4 inhibition.
The magnitude of DPP-4 inhibition following teneligliptin 20 mg daily appears to be at the best, modest, not exceeding >70% at 24 h. This outcome is perhaps, somewhat lower as seen in head-to-head study of sitagliptin, vildagliptin, and saxagliptin. Whether that translates into any lower glycemic efficacy with teneligliptin compared to other DPP-4Is is yet to be seen, as no head-to-head trial is being currently done or undergoing.
Teneligliptin 20 or 40 mg once daily studied for 12–16 weeks, in placebo-controlled trials, as a monotherapy or in combination with metformin, glimepiride, or pioglitazone, was found to improve glycemic control. Moreover, teneligliptin 40 mg daily was found to lower HbA1c to <7% in additional ~15%. Interestingly, HbA1c lowering efficacy of teneligliptin 20 mg daily in Indian studies appeared less appealing compared to Japanese and Korean trials despite similar baseline HbA1c across the trial. Moreover, there was no significant reduction in FPG with teneligliptin 20 mg daily compared to placebo, despite equivalent baseline FPG in Japanese and Korean studies.
Furthermore, no head-to-head trials currently exist against any active comparators although it is highly desirable. In contrast, trials exist with other four available DPP-4Is conducted against active comparator. In addition, safety of teneligliptin in patients with high CV risk or with existing CV disease and or chronic kidney disease is not yet known. Studies in such high-risk group to determine their safety and efficacy are highly desirable.
With regard to general safety, teneligliptin has been well tolerated in short-term studies, as well as in two 52 weeks extension studies, in combination therapy to glimepiride and pioglitazone. Lower hypoglycemia observed similar to placebo is similar in line with other DPP-4Is. However, long-term safety is still unknown. Significant increase in uric acid in one of the study needs further clarity.
While no obvious cardiac issues have been reported in these short-term trials, it should be noted that these studies were neither targeted nor powered to assess potential CV safety. And, thus a dedicated cardiovascular outcome trial (CVOT) is highly desirable. This appears really necessary and important given the difference in outcome with individual DPP-4Is. A significantly increased hospitalization due to heart failure (HHF) observed with saxagliptin in SAVOR-TIMI trials and in different subgroups of patients, as seen in subsequent post hoc analysis have already created a serious concern. Similar trend of HHF observed in EXAMINE and in some subgroups in post hoc analysis also with alogliptin have led to some controversy.,,,, This finding was seen in sharp contrast to sitagliptin CVOT trial (TECOS) which found no cardiac risk signal including HHF. Consequently, both saxagliptin and alogliptin have been recently given additional prescribing information of labeling of heart failure. It should be noted, however, that this decision of FDA is based on an independent re-analysis from the US FDA conducted in April 2015 which found a definite increase in HHF with saxagliptin and almost similar signals observed with alogliptin.
Although no dedicated CVOT is currently being conducted for teneligliptin, one TOPLEVEL (Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus) study is currently examining the effect of teneligliptin on diastolic echocardiographic parameters (E/e' ratio) as a primary outcome. TOPLEVEL is a 2-year (mean) study and expected to recruit ~936 T2DM patients of age 20 to 85 years with the ejection fraction of >40%, with expected completion in June 2019. This study appears to be similar in line to vildagliptin in VIVIDD trial and may give some solace to practicing clinician.
From cardiac safety point of view, prolongation of QTc is a unique issue with teneligliptin not observed with any other available DPP-4Is. Current threshold set by US FDA for cardiac safety of any drugs in Phase 1 trial is a drug should not prolong QTc by 5 ms or the upper bound 90% confidential interval (CI) of QTc studies should not cross the threshold of 10 ms. While teneligliptin 160 mg (although not recommended for clinical use) is clearly associated with a prolonged QTc, even teneligliptin 40 mg also appears to approach that critical threshold of 5 ms or upper bound 90% CI of 10 ms. This threshold perhaps becomes even more important when teneligliptin will be prescribed with several other drugs which tend to prolong QTc including antibiotics (azithromycin), antihistaminics (astemizole, terfenadine), diuretics (thiazide), selective serotonin uptake inhibitors, haloperidol, and obviously antiarrhythmic drugs (amiodarone and sotalol). Moreover, hypoglycemia being one of the strong QTc prolongators, combination with other hypoglycemic drug may need strict pharmacovigilance.
Overall, the present study will be a valuable addition to the accumulating data on teneligliptin. Particularly, the Indian evidence has been lacking and is therefore welcome. However, several questions remain, on the efficacy and “in particular” safety of teneligliptin as discussed earlier. A robust pharmacovigilance program to watch out for safety signals is important as are mechanized and clinical studies on CVOT, especially a dedicated CVOT given the QT prolongation.
Till then, health-care providers must keep in mind, the limitation of the data with teneligliptin and discuss the same with their patients.
| References|| |
Singh AK. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. Indian J Endocrinol Metab 2014;18:753-9.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al
. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement – Executive summary. Endocr Pract 2013;19:536-57.
Singh AK. Incretin response in Asian type 2 diabetes: Are Indians different? Indian J Endocrinol Metab 2015;19:30-8.
Deacon CF, Lebovitz HE. A Comparative Review of DPP-4 Inhibitors and Sulphonylureas. Diabetes Obes Metab 2016:18:333-47
Suryawanshi SY, Bhargava A, Agarwal P, Chamle V. Evaluation of safety and efficacy of teneligliptin in newly diagnosed Indian type 2 diabetes mellitus patients. 52nd
Annual Congress of European Association of Study in Diabetes, Munich. 2016, PS067; Abstract number 753.
Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, et al
. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-1-yl] pyrrolidin-2-ylcarbonyl] thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 2012;20:5705-19.
Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6.
Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:187-95.
Halabi A, Maatouk H, Siegler KE, Faisst N, Hinrichsen H. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharmacol Drug Dev 2014;3:290-6.
Nakamaru Y, Hayashi Y, Sekine M, Kinoshita S, Thompson J, Kawaguchi A, et al
. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: An open-label study in healthy white subjects in Germany. Clin Ther 2014;36:760-9.
Nakamaru Y, Hayashi Y, Davies M, Jurgen HH, Hisanaga N, Akimoto K. Investigation of potential pharmacokinetic interactions between teneligliptin and metformin in steady-state conditions in healthy adults. Clin Ther 2015;37:2007-18.
Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol 2015;11:7-14.
Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, et al
. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191-6.
Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. J Clin Med Res 2014;6:287-94.
Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:810-8.
Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, et al
. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: A 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 2016;18:528-32.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 2014;16:418-25.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2013;4:576-84.
Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, et al
. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: A 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 2015;17:309-12.
Pharmaceuticals and Medical Devices Agency (PMDA) Japan. Teneligliptin Review; 2012. Available from: https://www.pmda.go.jp/files/000153594.pdf. [Last accessed on 2016 May 20].
Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: A pooled analysis of two phase III clinical studies. Expert Opin Pharmacother 2015;16:971-81.
Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T. Safety and efficacy of teneligliptin: A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 2014;46:427-32.
Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, et al
. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther 2014;16:840-5.
Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, et al
. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J 2015;62:13-20.
Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol 2014;723:207-15.
Nakagami H, Pang Z, Shimosato T, Moritani T, Kurinami H, Koriyama H, et al
. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res 2014;37:629-35.
Morishita R, Nakagami H. Teneligliptin: Expectations for its pleiotropic action. Expert Opin Pharmcother 2015;16:417-26.
Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, et al
. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels 2015. [Epub ahead of print].
Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al
. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94.
Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-61.
García M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016;41:368-370.
Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, et al
. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther 2013;4:431-42.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al
. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al
. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-88.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al
. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al
. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al
. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Renoprotective effects of teneligliptin: An observational study
| ||Prabhat Agrawal,Ashish Gautam,Apoorva Jain,Nikhil Pursnani,Manjula S,KrishnaKumar M |
| ||Journal of Diabetology. 2021; 12(2): 146 |
|[Pubmed] | [DOI]|
||Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
| ||Da Hea Seo,Kyoung Hwa Ha,So Hun Kim,Dae Jung Kim |
| ||Endocrinology and Metabolism. 2021; 36(1): 70 |
|[Pubmed] | [DOI]|
||Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study
| ||Linong Ji,Ling Li,Jianhua Ma,Xuefeng Li,Dongmei Li,Bangzhu Meng,Weiping Lu,Jiao Sun,Yanmei Liu,Gen Takayanagi,Yi Wang |
| ||Endocrinology, Diabetes & Metabolism. 2021; |
|[Pubmed] | [DOI]|
||Teneligliptin-induced hair loss: A case report
| ||PrabhatK Agrawal,AshishK Gautam,Nikhil Pursnani,Akankshi Agarwal |
| ||Journal of Family Medicine and Primary Care. 2020; 9(5): 2552 |
|[Pubmed] | [DOI]|
||Is Teneligliptin Safe in Patients with Diabetes Mellitus Mainly with Reference to QT Prolongation
| ||Shrikrishna V. Acharya |
| ||Journal of Evolution of Medical and Dental Sciences. 2020; 9(31): 2171 |
|[Pubmed] | [DOI]|
||Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
| ||Masakazu Haneda,Takashi Kadowaki,Hiroshi Ito,Kazuyo Sasaki,Sonoe Hiraide,Manabu Ishii,Miyuki Matsukawa,Makoto Ueno |
| ||Diabetes Therapy. 2018; |
|[Pubmed] | [DOI]|